<p>都柏林，2026 年 2 月 13 日（全球新闻通讯社）——Trinity Biotech plc（纳斯达克：TRIB）是一家专注于人类诊断和糖尿病管理解决方案的商业阶段生物技术公司，包括可穿戴生物传感器。该公司于 2026 年 2 月 11 日收到纳斯达克证券市场有限责任公司（“纳斯达克”）的通知，指出公司未能遵守纳斯达克上市规则 5450(a)(1)，该规则要求上市证券的最低竞价价格保持在每股 1.00 美元以上，基于公司美国存托股票（“ADSs”）在过去 30 个连续交易日的收盘竞价价格。</p>
<p>该通知对公司 ADSs 的上市没有立即影响，ADSs 将继续在纳斯达克全球精选市场以 “TRIB” 符号交易。</p>
<p>根据纳斯达克上市规则 5810(c)(3)(A)，公司有 180 个日历天的时间，直到 2026 年 8 月 10 日，以重新符合最低竞价价格要求。为了重新符合要求，公司 ADSs 的收盘竞价价格必须在这 180 个日历天内至少连续十个交易日达到或超过 1.00 美元。如果公司未能重新符合要求，如果满足公众持股最低价值（“MVPHS”）（1500 万美元）和纳斯达克资本市场的所有其他初始上市标准（除了竞价价格），并在第二个合规期内向纳斯达克提供书面通知以修正缺陷，则公司可能有资格获得额外时间。</p>
<p>管理层打算积极监控其 ADSs 的竞价价格，并在规定的宽限期内修正缺陷。在此期间，公司预计其 ADSs 将继续在纳斯达克全球精选市场上市和交易。公司的管理层正在评估各种可用选项，以重新符合要求并维持其持续上市。</p>
<p><strong>前瞻性声明</strong></p>
<p>本发布包含根据 1995 年《私人证券诉讼改革法案》（“改革法”）的定义构成的 “前瞻性声明”，包括但不限于与 Trinity Biotech 的现金状况、财务资源和未来增长潜力、市场接受度和新产品或计划产品的渗透、未来经常性收入和运营结果相关的声明。Trinity Biotech 主张根据改革法对前瞻性声明的安全港保护。这些前瞻性声明通常以 “可能”、“相信”、“预计”、“期望”、“预期” 或类似含义的词语为特征，并不反映历史事实。本发布中包含的具体前瞻性声明可能受到风险和不确定性的影响，包括但不限于我们利用 Waveform 交易和最近收购的能力、我们在纳斯达克证券市场的持续上市、我们在未来实现盈利运营的能力、我们减少债务和改善资本结构的能力、COVID-19 及其变种传播的影响、美国政府对 Trinity Biotech 生产的 HIV 测试的资金可能暂停和/或中断、公司分销商的潜在过剩库存水平和库存失衡、与 Trinity Biotech 的设施或制造运营相关的损失或系统故障、汇率波动对国际运营的影响、季度运营结果的波动、对供应商的依赖、市场对 Trinity Biotech 产品和服务的接受度、产品的持续开发、所需的政府批准、与大规模无缺陷生产和分销其产品相关的风险、与第三方制造的新仪器引入相关的风险、在人体诊断市场竞争相关的风险、与保护 Trinity Biotech 的知识产权或第三方提出的知识产权侵权索赔相关的风险，以及与美国经济状况相关的风险，以及在 Trinity Biotech 截至 2024 年 12 月 31 日的财政年度的 20-F 表格年报和 Trinity Biotech 不时向美国证券交易委员会提交的其他定期报告中详细列出的 “风险因素”。前瞻性声明仅在声明发布之日有效。Trinity Biotech 不承担并明确拒绝更新任何前瞻性声明的义务。</p>
<p><strong>关于 Trinity Biotech</strong></p>
<p>Trinity Biotech 是一家专注于糖尿病管理解决方案和人类诊断的商业阶段生物技术公司，包括可穿戴生物传感器。该公司开发、收购、制造和销售诊断系统，包括用于即时护理和临床实验室领域的试剂和仪器，并最近通过收购 Waveform Technologies Inc.的生物传感器资产进入可穿戴生物传感器行业，计划开发一系列生物传感器设备和相关服务，首款产品为连续血糖监测产品。我们的产品用于检测传染病，并定量测定血清、血浆和全血中的糖化血红蛋白 A1c 及其他化学参数。Trinity Biotech 在美国直接销售，并通过国际分销商和战略合作伙伴在全球 75 个国家进行销售。有关更多信息，请访问公司网站：www.trinitybiotech.com。</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>联系人：</td>
<td><strong>Trinity Biotech plc</strong> Paul Murphy<br/>(353)-1-2769800</td>
<td><strong>RedChip Companies Inc.</strong><br/>Dave Gentry, CEO<br/>(1)-407-644-4256<br/>(1)-800-RED-CHIP (733-2447)<br/>TRIB@redchip.com</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMU5EZ3dOeU0zTkRJMU9EZ3dJekl3TVRnNU1UVT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMU5EZ3dOeU0zTkRJMU9EZ3dJekl3TVRnNU1UVT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YmE4YTdlOTctYmJjZi00YTJmLWFiODItYTFhODg5NWQ5NjA5LTEwMzA0ODgtMjAyNi0wMi0xMy1lbg==/tiny/Trinity-Biotech-plc.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YmE4YTdlOTctYmJjZi00YTJmLWFiODItYTFhODg5NWQ5NjA5LTEwMzA0ODgtMjAyNi0wMi0xMy1lbg==/tiny/Trinity-Biotech-plc.png"/></p>

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 3 倍做空 - Direxion

<p>Trinity Biotech plc（纳斯达克代码：TRIB）收到了纳斯达克关于其最低成交价格要求的非合规通知，因为其美国存托股票（ADS）连续 30 个交易日收盘价低于 1.00 美元。该公司有直到 2026 年 8 月 10 日的时间，通过维持至少 10 个连续交易日的成交价格在 1.00 美元以上来恢复合规。在此期间，ADS 将继续在纳斯达克全球精选市场交易，管理层正在探索解决该问题的方案</p>

<p>DUBLIN, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice on February 11, 2026 from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), requiring that listed securities maintain a minimum bid price of $1.00 per share, based on the closing bid price of the Company’s American Depositary Shares (“ADSs”) for the last 30 consecutive business days.</p>
<div class="lb-trans"><p>都柏林，2026 年 2 月 13 日（全球新闻通讯社）——Trinity Biotech plc（纳斯达克：TRIB）是一家专注于人类诊断和糖尿病管理解决方案的商业阶段生物技术公司，包括可穿戴生物传感器。该公司于 2026 年 2 月 11 日收到纳斯达克证券市场有限责任公司（“纳斯达克”）的通知，指出公司未能遵守纳斯达克上市规则 5450(a)(1)，该规则要求上市证券的最低竞价价格保持在每股 1.00 美元以上，基于公司美国存托股票（“ADSs”）在过去 30 个连续交易日的收盘竞价价格。</p>
</div><p>This notice has no immediate effect on the listing of the Company’s ADSs, which will continue to trade at this time on the Nasdaq Global Select Market under the symbol “TRIB.”</p>
<div class="lb-trans"><p>该通知对公司 ADSs 的上市没有立即影响，ADSs 将继续在纳斯达克全球精选市场以 “TRIB” 符号交易。</p>
</div><p>In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until August 10, 2026, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s ADSs must meet or exceed $1.00 for at least ten consecutive business days during this 180-calendar day period. In the event the Company does not regain compliance, the Company may be eligible for additional time if it meets the continued listing requirement for minimum value of publicly held shares (“MVPHS”) ($15,000,000) and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price and provides written notice to Nasdaq of its intention to cure the deficiency during the second compliance period.</p>
<div class="lb-trans"><p>根据纳斯达克上市规则 5810(c)(3)(A)，公司有 180 个日历天的时间，直到 2026 年 8 月 10 日，以重新符合最低竞价价格要求。为了重新符合要求，公司 ADSs 的收盘竞价价格必须在这 180 个日历天内至少连续十个交易日达到或超过 1.00 美元。如果公司未能重新符合要求，如果满足公众持股最低价值（“MVPHS”）（1500 万美元）和纳斯达克资本市场的所有其他初始上市标准（除了竞价价格），并在第二个合规期内向纳斯达克提供书面通知以修正缺陷，则公司可能有资格获得额外时间。</p>
</div><p>Management intends to actively monitor the bid price for its ADSs and to cure the deficiency within the prescribed grace period. During this time, the Company expects that the ADSs of the Company will continue to be listed and trade on the Nasdaq Global Select Market. The Company’s management is evaluating various options available to regain compliance and maintain its continued listing.</p>
<div class="lb-trans"><p>管理层打算积极监控其 ADSs 的竞价价格，并在规定的宽限期内修正缺陷。在此期间，公司预计其 ADSs 将继续在纳斯达克全球精选市场上市和交易。公司的管理层正在评估各种可用选项，以重新符合要求并维持其持续上市。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited to statements related to Trinity Biotech’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on the Waveform transaction and of our recent acquisitions, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, our ability to reduce our debt and improve our capitalization, the impact of the spread of COVID-19 and its variants, the possible pause and/or disruption in U.S. Government funding for HIV tests produced by Trinity Biotech, potential excess inventory levels and inventory imbalances at the company’s distributors, losses or system failures with respect to Trinity Biotech’s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech’s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotech’s intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy and other risks detailed under “Risk Factors” in Trinity Biotech’s annual report on Form 20-F for the fiscal year ended December 31, 2024 and Trinity Biotech’s other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not undertake and specifically disclaims any obligation to update any forward-looking statements.</p>
<div class="lb-trans"><p>本发布包含根据 1995 年《私人证券诉讼改革法案》（“改革法”）的定义构成的 “前瞻性声明”，包括但不限于与 Trinity Biotech 的现金状况、财务资源和未来增长潜力、市场接受度和新产品或计划产品的渗透、未来经常性收入和运营结果相关的声明。Trinity Biotech 主张根据改革法对前瞻性声明的安全港保护。这些前瞻性声明通常以 “可能”、“相信”、“预计”、“期望”、“预期” 或类似含义的词语为特征，并不反映历史事实。本发布中包含的具体前瞻性声明可能受到风险和不确定性的影响，包括但不限于我们利用 Waveform 交易和最近收购的能力、我们在纳斯达克证券市场的持续上市、我们在未来实现盈利运营的能力、我们减少债务和改善资本结构的能力、COVID-19 及其变种传播的影响、美国政府对 Trinity Biotech 生产的 HIV 测试的资金可能暂停和/或中断、公司分销商的潜在过剩库存水平和库存失衡、与 Trinity Biotech 的设施或制造运营相关的损失或系统故障、汇率波动对国际运营的影响、季度运营结果的波动、对供应商的依赖、市场对 Trinity Biotech 产品和服务的接受度、产品的持续开发、所需的政府批准、与大规模无缺陷生产和分销其产品相关的风险、与第三方制造的新仪器引入相关的风险、在人体诊断市场竞争相关的风险、与保护 Trinity Biotech 的知识产权或第三方提出的知识产权侵权索赔相关的风险，以及与美国经济状况相关的风险，以及在 Trinity Biotech 截至 2024 年 12 月 31 日的财政年度的 20-F 表格年报和 Trinity Biotech 不时向美国证券交易委员会提交的其他定期报告中详细列出的 “风险因素”。前瞻性声明仅在声明发布之日有效。Trinity Biotech 不承担并明确拒绝更新任何前瞻性声明的义务。</p>
</div><p><strong>About Trinity Biotech</strong></p>
<div class="lb-trans"><p><strong>关于 Trinity Biotech</strong></p>
</div><p>Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Our products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com.</p>
<div class="lb-trans"><p>Trinity Biotech 是一家专注于糖尿病管理解决方案和人类诊断的商业阶段生物技术公司，包括可穿戴生物传感器。该公司开发、收购、制造和销售诊断系统，包括用于即时护理和临床实验室领域的试剂和仪器，并最近通过收购 Waveform Technologies Inc.的生物传感器资产进入可穿戴生物传感器行业，计划开发一系列生物传感器设备和相关服务，首款产品为连续血糖监测产品。我们的产品用于检测传染病，并定量测定血清、血浆和全血中的糖化血红蛋白 A1c 及其他化学参数。Trinity Biotech 在美国直接销售，并通过国际分销商和战略合作伙伴在全球 75 个国家进行销售。有关更多信息，请访问公司网站：www.trinitybiotech.com。</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact:</td>
<td><strong>Trinity Biotech plc</strong> Paul Murphy<br/>(353)-1-2769800</td>
<td><strong>RedChip Companies Inc.</strong><br/>Dave Gentry, CEO<br/>(1)-407-644-4256<br/>(1)-800-RED-CHIP (733-2447)<br/>TRIB@redchip.com</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>联系人：</td>
<td><strong>Trinity Biotech plc</strong> Paul Murphy<br/>(353)-1-2769800</td>
<td><strong>RedChip Companies Inc.</strong><br/>Dave Gentry, CEO<br/>(1)-407-644-4256<br/>(1)-800-RED-CHIP (733-2447)<br/>TRIB@redchip.com</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMU5EZ3dOeU0zTkRJMU9EZ3dJekl3TVRnNU1UVT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTY1NDgwNyM3NDI1ODgwIzIwMTg5MTU="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YmE4YTdlOTctYmJjZi00YTJmLWFiODItYTFhODg5NWQ5NjA5LTEwMzA0ODgtMjAyNi0wMi0xMy1lbg==/tiny/Trinity-Biotech-plc.png" alt="" original-src="https://ml.globenewswire.com/media/YmE4YTdlOTctYmJjZi00YTJmLWFiODItYTFhODg5NWQ5NjA5LTEwMzA0ODgtMjAyNi0wMi0xMy1lbg==/tiny/Trinity-Biotech-plc.png"/></p>

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Nasdaq Minimum Bid Price Requirement | TRIB Stock News

StockTitan

Trinity Place控股

标普健康医疗设备 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

生物科技 ETF - VanEck Vectors

2 倍做多纳斯达克生物技术 ETF - ProShares

医药突破 ETF - ALPS

动态生物技术与基因组 ETF - Invesco

Trinity生物科技-A

美国医药设备 ETF - iShares

Trinity 生物科技收到关于纳斯达克全球精选市场最低出价要求的不合规通知 | TRIB 股票新闻